Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Key facts

Sponsor

Haihe Biopharma Co., Ltd.

Intervention

CYH33(drug)

Enrollment

141 target

Eligibility

All sexes

Timeline

2023 – 2029

Study locations (4)

• Capital Institute of Pediatrics, Beijing, Beijing Municipality, China
• Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
• Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
• West China Hospital of Sichuan University, Chengdu, Sichuan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for PIK3CA-related overgrowth syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06997588
  EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
  Novartis Pharmaceuticals
• RECRUITINGNANCT06840015
  Use of Airpod Pros as Assistive Technology
  The University of Texas at Dallas
• RECRUITINGPHASE2NCT06789913
  A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
  Relay Therapeutics, Inc.
• RECRUITINGNCT06956248
  Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
  National Cancer Centre, Singapore
• RECRUITINGNCT06364579
  Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• RECRUITINGNCT05898932
  Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
  Northwestern University
• ACTIVE NOT RECRUITINGNCT05705947
  PROs Following Low-dose Irradiation for Osteoarthritis
  University of North Carolina, Chapel Hill
• ACTIVE NOT RECRUITINGPHASE2NCT04980833
  Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
  Novartis Pharmaceuticals

See all trials for PIK3CA-related overgrowth syndrome →